Eplerenone is used alone or in combination with other medications to treat high blood pressure. Eplerenone is in a class of medications called mineralocorticoid receptor antagonists. It works by blocking the action of aldosterone, a natural substance in t + some more technical info. Technically, eplerenone is a selective antagonist at the mineralocorticoid receptor with markedly lower affinity for androgen and progesterone receptors than older aldosterone antagonists, producing natriuresis and attenuation of aldosterone driven fibrosis and remodeling in cardiovascular tissue. The molecule is a steroidal 9,11-epoxy derivative with molecular formula C24H30O6 and a molecular weight of about 414.5 g mol, administered orally, extensively metabolized by CYP3A4 to inactive metabolites, and eliminated primarily via hepatic routes; typical pharmacokinetic properties include peak plasma concentrations within a few hours and an elimination half life on the order of several hours, which supports once or twice daily dosing depending on indication. Clinically important considerations include potential for hyperkalemia, the need to monitor serum potassium and renal function, dose adjustments or avoidance with strong CYP3A4 inhibitors, and established efficacy in lowering blood pressure and reducing post myocardial infarction morbidity when indicated.
Parent: Eplerenone
Parent: Eplerenone
Parent: Eplerenone
Parent: Eplerenone
Parent: Eplerenone
Parent: Eplerenone
Parent: Eplerenone
Eplerenone API control programs characterize and limit related compounds and degradation products by validated chromatographic methods; typical specification practice for eplerenone batches includes limits for individual identified related compounds generally in the range of 0.1 to 0.5 percent by area or weight depending on compound toxicity and identification status, a tighter limit for any unspecified impurity often set at 0.1 percent or lower, and a total impurities limit commonly in the range of 1.0 to 2.0 percent. Common monitored related substances include ring opened or hydrolytic products of the epoxy lactone system, hydroxylated metabolites, demethylated species, and process related synthetic byproducts; genotoxic or otherwise toxicological relevant impurities are controlled to much lower thresholds consistent with ICH M7 guidance and local pharmacopeial requirements. Specifications and limits vary by manufacturer and regulatory filing, therefore batch certificates, regulatory dossiers, or pharmacopoeial monographs should be consulted for exact numeric limits applicable to a given supply.
Eplerenone is used to treat high blood pressure either alone or in combination with other drugs, and it is also indicated in specific cardiovascular settings such as post myocardial infarction heart failure to reduce morbidity. Its principal actions are blockade of aldosterone at the mineralocorticoid receptor, promotion of sodium excretion, reduction of fluid retention, and mitigation of aldosterone mediated cardiac and vascular remodeling.
Both drugs antagonize the mineralocorticoid receptor, but eplerenone is more selective with fewer off target effects at androgen and progesterone receptors, producing less gynecomastia and endocrine side effects than spironolactone. Spironolactone tends to be less expensive, has a longer clinical history, and in some cases stronger potassium sparing and diuretic effects, while eplerenone has a cleaner receptor selectivity profile and different drug interaction considerations.
Eplerenone is classified as a mineralocorticoid receptor antagonist and produces natriuresis and modest diuretic effects by blocking aldosterone mediated sodium retention, but it is not a loop or thiazide diuretic. Its clinical benefit is as an aldosterone antagonist that reduces fluid overload and adverse remodeling rather than as a primary high potency diuretic.
Disadvantages include risk of hyperkalemia especially in patients with reduced renal function or when combined with other potassium raising agents, potential interactions with strong CYP3A4 inhibitors which can raise drug exposure, the need for laboratory monitoring of potassium and renal function, higher cost relative to some alternatives, and a shorter clinical experience compared with older agents such as spironolactone.
